Blog Posts
Bloomberg Law: “Chilling Effect” of FTC & DOJ’s Aggressive M&A Enforcement Approach
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive deals that pose no antitrust harms.
Innovations Advanced by M&A: A First-In-Class Treatment for Hypertrophic Cardiomyopathy
Mergers and acquisitions (M&A) are a vital mechanism for transitioning treatments currently in development to approved medicines available to the patients who need them the most. In one such example, the synergies from a life science acquisition brought a revolutionary therapy for hypertrophic cardiomyopathy (HCM) to patients.
Concurrences Law & Economics: Life Sciences M&A Brings Together Complementary Resources, Expertise
For life science companies of all sizes, competitive mergers and acquisitions (M&A) serve as a critical driver in bringing new and groundbreaking treatments and cures to market. In a recent article published in Concurrences Law and Economics, economists from Cornerstone Research highlight the many ways in which M&A supports biopharmaceutical innovation.
CSIS Report: Supporting Pro-Competitive M&A Is Critical to U.S. Leadership in Biopharmaceutical Innovation
Protecting and promoting collaboration across the U.S. life sciences ecosystem remains a driving force in bringing new breakthroughs to patients, according to a recent report from the Center for Strategic and International Studies (CSIS).
ABA Antitrust Podcast: Balanced Approach is Critical to Assessing the Impact of Life Sciences M&A on Innovation
On a recent episode of the ABA Antitrust Podcast Our Curious Amalgam, Dr. Penka Kovacheva, Cornerstone Research Vice President and lead author of a paper recently published in Concurrences, “The Impact of Pharmaceutical M&A on Innovation,” discusses many ways in which mergers and acquisitions (M&A) can contribute to biopharmaceutical innovation.
ICYMI – BioPharma Dive: Increased Biopharmaceutical M&A Critical to Supporting Early-Stage Breakthroughs
A recent article from BioPharma Dive highlights the challenging landscape for biopharmaceutical initial public offerings (IPOs), and the critical role that mergers & acquisitions play in connecting promising innovations with the resources and investment needed to bring new, early-stage innovations to patients.
Concurrences Law & Economics: M&A Unlocks Economies of Scale and Scope Across the Life Sciences Ecosystem
In a recent article published in Concurrences Law & Economics, Cornerstone Research experts highlight ways that mergers and acquisitions (M&A) can contribute to innovation in the biopharmaceutical industry. Among these, the authors contend that M&A and similar collaborations allow life sciences companies to unlock economies of scale and scope and innovate more efficiently.
ICYMI: Ways and Means Field Hearing –Policymakers Must Take a Balanced, Bipartisan Approach to Life Sciences M&A
The U.S. House Committee on Ways and Means recently held a field hearing in Salt Lake City, UT: “Access to Health Care in America: Unleashing Medical Innovation and Economic Prosperity.”
Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers
By combining complementary resources and expertise among companies of all sizes – while driving investment across the ecosystem – M&A helps advance innovative new treatments and cures to patients. This was precisely the case for Retevmo and Jaypirica, two first-of-their-kind oncology treatments brought to market through the acquisition of Loxo Oncology by Eli Lilly & Co.
New Research Article: The impact of pharmaceutical M&A on innovation
Mergers and acquisitions (M&A) play a unique and fundamental role in the development of new treatments and cures across the pharmaceutical ecosystem. A research article published yesterday, “The impact of pharmaceutical M&A on innovation: Insights from the literature” by competition and economics experts from Cornerstone Research, explores this in depth.